Antenatal management of congenital diaphragmatic hernia today and tomorrow

Lennart van der Veeken; Francesca M Russo; Johannes van der Merwe; David Basurto; Dyuti Sharma; Tram Nguyen; Marie P Eastwood; Namesh Khoshgoo; Jaan Toelen; Karel Allegaert; Philip Dekoninck; Stuart B Hooper; Richard Keijzer; Paolo De Coppi; Jan Deprest

doi:10.23736/S0026-4946.18.05186-1

Antenatal management of congenital diaphragmatic hernia today and tomorrow

Lennart van der Veeken, Francesca M Russo, Johannes van der Merwe, David Basurto, Dyuti Sharma, Tram Nguyen, Marie P Eastwood, Namesh Khoshgoo, Jaan Toelen, Karel Allegaert, Philip Dekoninck, Stuart B Hooper, Richard Keijzer, Paolo De Coppi, Jan Deprest^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic

7 Citations (Scopus)

Abstract

Congenital diaphragmatic hernia is rare birth defect, which can be easily corrected after birth. The main problem is that herniation of viscera during fetal life impairs lung development, leading to a 30% mortality and significant morbidity. In isolated cases the outcome can be accurately predicted prenatally by medical imaging. Cases with a poor prognosis can be treated before birth; clinically this is by fetoscopic endoluminal tracheal occlusion. Obstruction of the airways triggers lung growth. This procedure is currently being evaluated in a global clinical trial for left sided cases; right sided cases with poor prognosis are offered the procedure clinically. The search for more potent and less invasive therapies continues. Prenatal transplacental sildenafil administration will in due course be tried clinically, with the aim to reduce the occurrence of persistent pulmonary hypertension, either alone or in combination with fetal surgery. Other medical approaches are in an earlier translational phase.

Original language	English
Pages (from-to)	270-280
Number of pages	11
Journal	Minerva Pediatrica
Volume	70
Issue number	3
DOIs	https://doi.org/10.23736/S0026-4946.18.05186-1
Publication status	Published - Jun 2018
Externally published	Yes

Bibliographical note

Funding sources:
J.D.P. was a Clinical Researcher of the Flanders Research Foundation (FWO Vlaanderen; 1.8.01207) and
is partly funded by GOSH Children’s Charity. RK is Thorlakson Chair in Surgical Research and the
recipient of a Career Development Award from the Canadian Child Health Clinician Scientist Program
and a New Investigator Salary Award from the Canadian Institutes of Health Research/Manitoba Lung
Association/Children’s Hospital Research Institute of Manitoba. P.D.C. is an NIHR Professor and
supported by the Catapult Cell Therapy, the GOSH Children’s Charity, and GOSH NIHR Biomedical
Research Centre’s funding scheme. Our research into CDH is funded by the KU Leuven (IOF/C3),
GOSHCC, Sparks, CDHUK, Canadian Institutes of Health Research, Fetal Health Foundation (Brianna
Marie) and by an Innovative Engineering for Health award by the Wellcome Trust (WT101957), the
Engineering and Physical Sciences Research Council (NS/A000027/1). L.v.V., F.R., T.N., P.E. and D.B. are
supported by the Erasmus+ Program of the European Commission (2013-0040). This publication
reflects the views only of the author, and the Commission cannot be held responsible for any use which
may be made of the information contained therein. * PDK is currently working at the Erasmus Medical
Centre, Rotterdam, the Netherlands.

Access to Document

10.23736/S0026-4946.18.05186-1

Cite this

van der Veeken, L., Russo, F. M., van der Merwe, J., Basurto, D., Sharma, D., Nguyen, T., Eastwood, M. P., Khoshgoo, N., Toelen, J., Allegaert, K., Dekoninck, P., Hooper, S. B., Keijzer, R., De Coppi, P., & Deprest, J. (2018). Antenatal management of congenital diaphragmatic hernia today and tomorrow. Minerva Pediatrica, 70(3), 270-280. https://doi.org/10.23736/S0026-4946.18.05186-1

@article{87b8df9295e9460c9d58ccd9d347d4d6,

title = "Antenatal management of congenital diaphragmatic hernia today and tomorrow",

abstract = "Congenital diaphragmatic hernia is rare birth defect, which can be easily corrected after birth. The main problem is that herniation of viscera during fetal life impairs lung development, leading to a 30% mortality and significant morbidity. In isolated cases the outcome can be accurately predicted prenatally by medical imaging. Cases with a poor prognosis can be treated before birth; clinically this is by fetoscopic endoluminal tracheal occlusion. Obstruction of the airways triggers lung growth. This procedure is currently being evaluated in a global clinical trial for left sided cases; right sided cases with poor prognosis are offered the procedure clinically. The search for more potent and less invasive therapies continues. Prenatal transplacental sildenafil administration will in due course be tried clinically, with the aim to reduce the occurrence of persistent pulmonary hypertension, either alone or in combination with fetal surgery. Other medical approaches are in an earlier translational phase.",

author = "{van der Veeken}, Lennart and Russo, {Francesca M} and {van der Merwe}, Johannes and David Basurto and Dyuti Sharma and Tram Nguyen and Eastwood, {Marie P} and Namesh Khoshgoo and Jaan Toelen and Karel Allegaert and Philip Dekoninck and Hooper, {Stuart B} and Richard Keijzer and {De Coppi}, Paolo and Jan Deprest",

note = "Funding sources: J.D.P. was a Clinical Researcher of the Flanders Research Foundation (FWO Vlaanderen; 1.8.01207) and is partly funded by GOSH Children{\textquoteright}s Charity. RK is Thorlakson Chair in Surgical Research and the recipient of a Career Development Award from the Canadian Child Health Clinician Scientist Program and a New Investigator Salary Award from the Canadian Institutes of Health Research/Manitoba Lung Association/Children{\textquoteright}s Hospital Research Institute of Manitoba. P.D.C. is an NIHR Professor and supported by the Catapult Cell Therapy, the GOSH Children{\textquoteright}s Charity, and GOSH NIHR Biomedical Research Centre{\textquoteright}s funding scheme. Our research into CDH is funded by the KU Leuven (IOF/C3), GOSHCC, Sparks, CDHUK, Canadian Institutes of Health Research, Fetal Health Foundation (Brianna Marie) and by an Innovative Engineering for Health award by the Wellcome Trust (WT101957), the Engineering and Physical Sciences Research Council (NS/A000027/1). L.v.V., F.R., T.N., P.E. and D.B. are supported by the Erasmus+ Program of the European Commission (2013-0040). This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein. * PDK is currently working at the Erasmus Medical Centre, Rotterdam, the Netherlands. ",

year = "2018",

month = jun,

doi = "10.23736/S0026-4946.18.05186-1",

language = "English",

volume = "70",

pages = "270--280",

journal = "Minerva Pediatrica",

issn = "0026-4946",

number = "3",

}

van der Veeken, L, Russo, FM, van der Merwe, J, Basurto, D, Sharma, D, Nguyen, T, Eastwood, MP, Khoshgoo, N, Toelen, J, Allegaert, K , Dekoninck, P, Hooper, SB, Keijzer, R, De Coppi, P & Deprest, J 2018, 'Antenatal management of congenital diaphragmatic hernia today and tomorrow', Minerva Pediatrica, vol. 70, no. 3, pp. 270-280. https://doi.org/10.23736/S0026-4946.18.05186-1

TY - JOUR

T1 - Antenatal management of congenital diaphragmatic hernia today and tomorrow

AU - van der Veeken, Lennart

AU - Russo, Francesca M

AU - van der Merwe, Johannes

AU - Basurto, David

AU - Sharma, Dyuti

AU - Nguyen, Tram

AU - Eastwood, Marie P

AU - Khoshgoo, Namesh

AU - Toelen, Jaan

AU - Allegaert, Karel

AU - Dekoninck, Philip

AU - Hooper, Stuart B

AU - Keijzer, Richard

AU - De Coppi, Paolo

AU - Deprest, Jan

N1 - Funding sources: J.D.P. was a Clinical Researcher of the Flanders Research Foundation (FWO Vlaanderen; 1.8.01207) and is partly funded by GOSH Children’s Charity. RK is Thorlakson Chair in Surgical Research and the recipient of a Career Development Award from the Canadian Child Health Clinician Scientist Program and a New Investigator Salary Award from the Canadian Institutes of Health Research/Manitoba Lung Association/Children’s Hospital Research Institute of Manitoba. P.D.C. is an NIHR Professor and supported by the Catapult Cell Therapy, the GOSH Children’s Charity, and GOSH NIHR Biomedical Research Centre’s funding scheme. Our research into CDH is funded by the KU Leuven (IOF/C3), GOSHCC, Sparks, CDHUK, Canadian Institutes of Health Research, Fetal Health Foundation (Brianna Marie) and by an Innovative Engineering for Health award by the Wellcome Trust (WT101957), the Engineering and Physical Sciences Research Council (NS/A000027/1). L.v.V., F.R., T.N., P.E. and D.B. are supported by the Erasmus+ Program of the European Commission (2013-0040). This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein. * PDK is currently working at the Erasmus Medical Centre, Rotterdam, the Netherlands.

PY - 2018/6

Y1 - 2018/6

N2 - Congenital diaphragmatic hernia is rare birth defect, which can be easily corrected after birth. The main problem is that herniation of viscera during fetal life impairs lung development, leading to a 30% mortality and significant morbidity. In isolated cases the outcome can be accurately predicted prenatally by medical imaging. Cases with a poor prognosis can be treated before birth; clinically this is by fetoscopic endoluminal tracheal occlusion. Obstruction of the airways triggers lung growth. This procedure is currently being evaluated in a global clinical trial for left sided cases; right sided cases with poor prognosis are offered the procedure clinically. The search for more potent and less invasive therapies continues. Prenatal transplacental sildenafil administration will in due course be tried clinically, with the aim to reduce the occurrence of persistent pulmonary hypertension, either alone or in combination with fetal surgery. Other medical approaches are in an earlier translational phase.

AB - Congenital diaphragmatic hernia is rare birth defect, which can be easily corrected after birth. The main problem is that herniation of viscera during fetal life impairs lung development, leading to a 30% mortality and significant morbidity. In isolated cases the outcome can be accurately predicted prenatally by medical imaging. Cases with a poor prognosis can be treated before birth; clinically this is by fetoscopic endoluminal tracheal occlusion. Obstruction of the airways triggers lung growth. This procedure is currently being evaluated in a global clinical trial for left sided cases; right sided cases with poor prognosis are offered the procedure clinically. The search for more potent and less invasive therapies continues. Prenatal transplacental sildenafil administration will in due course be tried clinically, with the aim to reduce the occurrence of persistent pulmonary hypertension, either alone or in combination with fetal surgery. Other medical approaches are in an earlier translational phase.

U2 - 10.23736/S0026-4946.18.05186-1

DO - 10.23736/S0026-4946.18.05186-1

M3 - Review article

C2 - 29479945

SN - 0026-4946

VL - 70

SP - 270

EP - 280

JO - Minerva Pediatrica

JF - Minerva Pediatrica

IS - 3

ER -

Antenatal management of congenital diaphragmatic hernia today and tomorrow

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this